Tramadol + Placebo
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Post-Traumatic Stress Disorder
Conditions
Post-Traumatic Stress Disorder
Trial Timeline
Sep 1, 2011 → Aug 1, 2015
NCT ID
NCT01517711About Tramadol + Placebo
Tramadol + Placebo is a approved stage product being developed by Brain Biotech for Post-Traumatic Stress Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01517711. Target conditions include Post-Traumatic Stress Disorder.
What happened to similar drugs?
2 of 6 similar drugs in Post-Traumatic Stress Disorder were approved
Approved (2) Terminated (3) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01517711 | Approved | Completed |
Competing Products
16 competing products in Post-Traumatic Stress Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab-Gnlm | Eli Lilly | Approved | 43 |
| Quetiapine Fumarate + quetiapine fumarate placebo | AstraZeneca | Phase 3 | 40 |
| Rizatriptan + Placebo | Merck | Pre-clinical | 18 |
| AMG 334 | Novartis | Phase 2 | 35 |
| Balovaptan + Placebo | Roche | Phase 2 | 35 |
| Erenumab | Amgen | Phase 2 | 35 |
| PF-04457845 + Placebo | Pfizer | Phase 2 | 27 |
| Zoloft (Sertraline) | Pfizer | Phase 3 | 32 |
| Levetiracetam + Placebo | UCB | Phase 3 | 32 |
| levetiracetam + Placebo + Levetriracetam | UCB | Phase 2/3 | 38 |
| Placebo + Brexpiprazole | Lundbeck | Phase 3 | 29 |
| Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo | Lundbeck | Phase 2 | 32 |
| AbobotulinumtoxinA + Normal saline | Ipsen | Approved | 40 |
| Nabiximols + Placebo | Jazz Pharmaceuticals | Phase 2/3 | 27 |
| 60 mg PRAX-114 or 40 mg PRAX-114 + Placebo + 40 mg PRAX-114 | Praxis Precision Medicines | Phase 2 | 24 |
| MDMA | Nautilus Biotechnology | Phase 2 | 50 |